Home › Research › Clinical trials
Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia
JANICE E. CHRISTIE, A. Shering, James M. Ferguson, A.I.M. Glen. The British Journal of Psychiatry, 1981-01-01
Topic: Drug trials: efficacy and safety
Plain-language summary
Physostigmine (0.25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia. Significant improvement was seen on a picture recognition test with physostigmine 0.375 mg and arecholine 4 mg. A trend towards improvement was also seen with physostigmine 0.25 mg and 0.75 mg, and arecholine 2 mg. For the majority of the patients improvement was only slight but in two patients it was clear cut and consistent.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
CHRISTIE, J. E., Shering, A., Ferguson, J. M., & Glen, A. (1981). Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.138.1.46
Vancouver
CHRISTIE JE, Shering A, Ferguson JM, Glen A. Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia. The British Journal of Psychiatry. 1981. doi:10.1192/bjp.138.1.46. PMID: 7023592.
BibTeX
@article{christie1981-7023592,
author = {CHRISTIE, JANICE E. and Shering, A. and Ferguson, James M. and Glen, A.I.M.},
title = {{Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia}},
journal = {The British Journal of Psychiatry},
year = {1981},
doi = {10.1192/bjp.138.1.46},
pmid = {7023592},
url = {https://doi.org/10.1192/bjp.138.1.46}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Significant improvement was seen on a picture recognition test with physostigmine 0.375 mg and arecholine 4 mg.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Evidence strengthHigh
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The British Journal of Psychiatry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1981 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 7023592) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.